About this author
Zack Lynch is author of The Neuro Revolution: How Brain Science Is Changing Our World (St. Martin's Press, July 2009).
He is the founder and executive director of the Neurotechnology Industry Organization (NIO) and co-founder of NeuroInsights. He serves on the advisory boards of the McGovern Institute for Brain Research at MIT, the Center for Neuroeconomic Studies, Science Progress, and SocialText, a social software company. Please send newsworthy items or feedback - to Zack Lynch.
Follow me on Twitter at @neurorev
Receive by email

TNRCoverWeb120.jpg Buy on Amazon

Brain Waves

Category Archives

« NBIC 03-04-05 | NERV - Neurotech Index | Neuro Revolution »

July 2, 2008

Nasdaq NeuroInsights Neurotech Index Update

Email This Entry

Posted by Zack Lynch

NERV0608.pngThe NASDAQ NeuroInsights Neurotech Index (NERV) underwent its biannual assessment resulting in the addition of three companies Adolor (ADLR), Noven (NOVN) and Somanetics (SMTS) and the loss of seven whose market cap dropped below the $200 million minimum, namely Alexza (ALXA), Aspect Medical (ASPM), Javelin (JAV), Micrus (MEND), Neurocrine (NBIX), Northstar Neuroscience (NSTR), and Vanda Pharmaceuticals (VNDA). Realtime quote of NERV.

Index Performance: As of June 30, historical back-testing indicates that ^NERV is up 9% from a theoretical start date of June 2005, compared to respective gains of 7.5% and 17% for the S&P 500 and the NASDAQ Biotech Index. The historical values prior to the Index launch are based on NASDAQ’s calculation of how the index may have performed over time if it existed. The back-tested Index Values are purely hypothetical and are solely for information purposes only. Back-tested Index Values do not represent actual Index performance and are not indicative of actual Index performance. The index began calculation on September 25, 2007.

Comments (0) + TrackBacks (0) | Category: NERV - Neurotech Index

October 2, 2007

NERV - NASDAQ NeuroInsights Neurotech Index is Live

Email This Entry

Posted by Zack Lynch


NERV, the Nasdaq NeuroInsights Neurotech Index was launched last week and is now live. NIO and NeuroInsights hosted a media tour in NYC for several executives from Neurotech index companies including, Uli Hacksell, CEO of ACADIA Pharmaceuticals; Jim Brown, CEO of DURECT Corporation; Ron Cohen, CEO of Acorda Therapeutics; Elliot Ehrich, CMO of Alkermes; and David Hung, CEO of Medivation. Casey and I and the executives traveled to Forbes where we met met with Bob Langreth and Matt Herper at Forbes, five reporters at the Wall Street Journal and the editorial team at Scientific American Mind. To track NERV I recommend going to or Yahoo Finance and type in ^NERV(the ^ symbol is used for indices).

Comments (1) + TrackBacks (0) | Category: NERV - Neurotech Index